Efficacy of Combining Upadacitinib and Intense Pulsed Light for the Treatment of Erythematous Rosacea
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/6653760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 18.05.2026. Verfasst von Yinping Chen und 1 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research and Development, Yangtze University.
Abstract (Originalsprache)
Objective
This preliminary hypothesis‐generating study aimed to explore the potential efficacy of combining upadacitinib with intense pulsed light (IPL) in patients with erythematous rosacea and generate preliminary hypotheses for subsequent confirmatory testing.
Methods
Twenty‐one patients with erythematous rosacea were included in the nonrandomized, exploratory analysis. Of these, 15 patients received combined treatment with upadacitinib and IPL, while the control group of 6 patients was given IPL monotherapy. Clinical outcomes were evaluated using a skin analyzer, with quantification of erythema intensity (relative intensity of redness [RIR]) and area (percentage of erythema area [PEA]) using ImageJ software. The Clinician’s Erythema Assessment (CEA) and the Dermatology Life Quality Index (DLQI) were also applied.
Results
Significantly reduced PEA values were observed in the combination group (median: −27.70%, IQR: −51.60 to −17.30) compared to the IPL monotherapy group (median: −2.865%, IQR: −17.35 to 1.700) ( p = 0.0024). However, there was no difference in the RIR values between the two groups ( p = 0.2123). Although transient papules occurred in three patients in the combination group, no serious adverse events were reported. The assessments were corroborated by both clinicians and patients using the CEA and DLQI, respectively.
Conclusion
These preliminary findings from a small‐scale, exploratory study suggest the potential utility of the combination of upadacitinib and IPL in reducing erythema area. The results provide preliminary hypothesis‐generating data and a rationale for further verification or refutation of the observed trends in this study. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2600122212.
Förderung
- Research and Development
- Yangtze University
Zitieren
APA
Chen, Y., & Sun, Y. (2026). Efficacy of Combining Upadacitinib and Intense Pulsed Light for the Treatment of Erythematous Rosacea. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/6653760
Vancouver
Chen Y, Sun Y. Efficacy of Combining Upadacitinib and Intense Pulsed Light for the Treatment of Erythematous Rosacea. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/6653760
BibTeX
@article{Chen2026,
author = {Chen, Yinping and Sun, Yi},
title = {Efficacy of Combining Upadacitinib and Intense Pulsed Light for the Treatment of Erythematous Rosacea},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/6653760}
}
EUVIMED